Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative Xuebijing to Reduce Lung Injury After Cardiopulmonary Bypass
ChiCTR-IPR-16009644Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Oct 2016
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of xuebijing in not applicable; "lung injury" is not a specific disease and Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoint: PaO2/FiO2 at 24 h post-operation. Started Oct 2016; status: recruiting.
02
Drugs
xuebijing
03
Conditions
not applicable; "lung injury" is not a specific diseaseSystemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on ChiCTR-IPR-16009644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009644.